Omada Health Inc. rang the opening bell on the New York Stock Exchange on June 6, marking its first day as a public company, ...

In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant and clinically meaningful cuts in low ...

Absent extraordinary circumstances, the Patent Trial and Appeal Board “should never cancel claims it has not determined to be unpatentable as a sanction” for misconduct during a board proceeding, ...

The top 10 med-tech stock gainers and losers for the week.

Turning the human body into a biofactory of precision protein therapeutics is the focus of newly launched Signify Bio, which ...

Biopharma financings totaled $21.38 billion through May 2025, down sharply from $62.57 billion during the same period in 2024 ...

Researchers from the University of Arizona have unveiled that coordinated Y chromosome loss in both cancer cells and immune ...

Microneedle technology could help simplify vaccine delivery to better support global immunization efforts, and Australia is ...

Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual ...

Transpire Bio Inc. has signed an exclusive license agreement with Suzhou Intragrand Pharma Co. Ltd. for ITG-1052 (lenamilast) ...

Human adenovirus may cause severe infections in both immunosuppressed and immunocompetent individuals and there is no ...

Bioage Labs Inc. is advancing its apelin receptor (APJ) agonist programs for obesity and other indications, and has entered ...